期刊
CANCER LETTERS
卷 479, 期 -, 页码 54-60出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.10.024
关键词
Cancer testis antigen; Sarcoma; Expression; Function; Immunotherapy
类别
资金
- Department of Orthopaedic Surgery at UCLA
- Sarcoma Foundation of America (SFA) [222433]
- National Cancer Institute (NCI), National Institutes of Health (NIH) [CA151452-01]
Sarcomas are a group of heterogeneous malignancies of mesenchymal origin. Patient outcomes remain especially grim for those with recurrent or metastatic disease, and current therapeutic strategies have not significantly improved outcomes over the past few decades. This has led to a number of studies assessing novel therapies. Cancer testis antigens (CTAs) are tumor-associated antigens with physiologic expression in the testis and various malignancies, including sarcomas. Genes encoding CTAs include MAGE, NY-ESO-1, PRAME, TRAG-3/CSAGE, and SSX. The importance and function of CTAs in tumorigenesis have gained recognition in recent years. They are also proving as robust diagnostic and prognostic biomarkers. Therapeutically, antigens derived from CTAs are highly recognizable by T lymphocytes and therefore capable of generating a potent antitumor immune response. CTAs are, therefore, promising targets for novel immunotherapies. Here we review the emerging works on expression, function, and immunotherapeutic application of CTAs in sarcoma therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据